Toll Free: 1-888-928-9744

Bionomics Limited - Product Pipeline Review - 2014

Published: Nov, 2014 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Bionomics Limited - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Bionomics Limited - Product Pipeline Review - 2014', provides an overview of the Bionomics Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Bionomics Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Bionomics Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Bionomics Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Bionomics Limited's pipeline products

Reasons to buy

- Evaluate Bionomics Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Bionomics Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Bionomics Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Bionomics Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bionomics Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Bionomics Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Bionomics Limited Snapshot 5
Bionomics Limited Overview 5
Key Information 5
Key Facts 5
Bionomics Limited - Research and Development Overview 6
Key Therapeutic Areas 6
Bionomics Limited - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Bionomics Limited - Pipeline Products Glance 13
Bionomics Limited - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Bionomics Limited - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Bionomics Limited - Drug Profiles 17
BNC-105 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
BNC-105P 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
BNC-210 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
BL-011256 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
BNC-101 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
BNC-164 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
BNC-420 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
BNC-102 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Programs for Cancer 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecules to Agonize GABA-A Receptor For Epilepsy 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Bionomics Limited - Pipeline Analysis 30
Bionomics Limited - Pipeline Products by Target 30
Bionomics Limited - Pipeline Products by Route of Administration 31
Bionomics Limited - Pipeline Products by Molecule Type 32
Bionomics Limited - Pipeline Products by Mechanism of Action 33
Bionomics Limited - Recent Pipeline Updates 34
Bionomics Limited - Dormant Projects 38
Bionomics Limited - Discontinued Pipeline Products 39
Discontinued Pipeline Product Profiles 39
Drug to Inhibit RET Kinase for Lung and Thyroid Cancer 39
Bionomics Limited - Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42
List of Tables
Bionomics Limited, Key Information 5
Bionomics Limited, Key Facts 5
Bionomics Limited - Pipeline by Indication, 2014 7
Bionomics Limited - Pipeline by Stage of Development, 2014 9
Bionomics Limited - Monotherapy Products in Pipeline, 2014 10
Bionomics Limited - Out-Licensed Products in Pipeline, 2014 11
Bionomics Limited - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
Bionomics Limited - Phase II, 2014 13
Bionomics Limited - Phase I, 2014 14
Bionomics Limited - Preclinical, 2014 15
Bionomics Limited - Discovery, 2014 16
Bionomics Limited - Pipeline by Target, 2014 30
Bionomics Limited - Pipeline by Route of Administration, 2014 31
Bionomics Limited - Pipeline by Molecule Type, 2014 32
Bionomics Limited - Pipeline Products by Mechanism of Action, 2014 33
Bionomics Limited - Recent Pipeline Updates, 2014 34
Bionomics Limited - Dormant Developmental Projects,2014 38
Bionomics Limited - Discontinued Pipeline Products, 2014 39
Bionomics Limited, Subsidiaries 40 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify